Synergy of Karenitecin and Mafosfamide in Pediatric Leukemia, Medulloblastoma, and Neuroblastoma Cell Lines

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2007 Sep 13

PMID 17849472

Citations 1

Authors

Eufemia Jacob

Kathy Scorsone

Susan M Blaney

David Z DArgenio

Stacey L Berg

Affiliations

Soon will be listed here.

Abstract

Background: A major barrier to treatment of leptomeningeal disease is the lack of proven combination chemotherapy regimens for intrathecal administration. The purpose of this study was to determine the cytotoxic effects of karenitecin and mafosfamide in vitro against leukemia, medulloblastoma, and neuroblastoma cell lines.

Procedure: A modified methyl tetrazolium (MTT) assay was used to determine the sensitivity of the cells to karenitecin and mafosfamide. Cells were exposed to drug for 72 hr, after which the number of surviving cells was quantitated. For drug combination experiments, cells were exposed to medium alone (controls), single drugs alone (mafosfamide only, karenitecin only) or to different concentrations of the combination of the two drugs (karenitecin + mafosfamide), for a total of 36 concentration pairs per plate. The universal response surface approach (URSA) was used to analyze the cytotoxic effects of the combination of karenitecin and mafosfamide.

Results: The IC(50)s of karenitecin and mafosfamide for the various cell lines were similar. For both drugs nearly complete inhibition of cell growth was demonstrated at higher concentrations in all cell lines. In the neuroblastoma cell lines (SK-N-DZ; SK-N-SH) and the DAOY medulloblastoma cell line, the combination of karenitecin and mafosfamide were synergistic. In the D283 medulloblastoma and both the leukemia cell lines (JM1 and Molt-4), the drug interaction was additive. Antagonism was not seen in any cell line.

Conclusions: Karenitecin and mafosfamide are additive or synergistic in vitro against tumor types that disseminate to the leptomeninges. These results provide guidance for the choice of potential combination intrathecal regimens.

Citing Articles

Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001).

Blaney S, Kocak M, Gajjar A, Chintagumpala M, Merchant T, Kieran M J Neurooncol. 2012; 109(3):565-71.

PMID: 22790443 PMC: 3529096. DOI: 10.1007/s11060-012-0929-x.

References

Slavc I, Schuller E, Czech T, Hainfellner J, Seidl R, Dieckmann K . Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol. 1998; 38(2-3):213-8. DOI: 10.1023/a:1005940405165. View

Blaney S, Poplack D . New cytotoxic drugs for intrathecal administration. J Neurooncol. 1998; 38(2-3):219-23. DOI: 10.1023/a:1005944622003. View

Hausheer F, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D . Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Semin Oncol. 1998; 25(5):584-99. View

Blaney S, Balis F, Berg S, Arndt C, Heideman R, Geyer J . Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005; 23(7):1555-63. DOI: 10.1200/JCO.2005.06.053. View

Horton T, Gannavarapu A, Blaney S, DArgenio D, Plon S, Berg S . Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2005; 58(1):13-23. DOI: 10.1007/s00280-005-0135-z. View

Kerr J, Berg S, Blaney S . Intrathecal chemotherapy. Crit Rev Oncol Hematol. 2001; 37(3):227-36. DOI: 10.1016/s1040-8428(00)00115-3. View

Blaney S, Heideman R, Berg S, Adamson P, Gillespie A, Geyer J . Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2002; 21(1):143-7. DOI: 10.1200/JCO.2003.04.053. View

Slavc I, Schuller E, Falger J, Gunes M, Pillwein K, Czech T . Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. J Neurooncol. 2003; 64(3):239-47. DOI: 10.1023/a:1025633704071. View

Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

10.

Alberts D, Einspahr J, Struck R, Bignami G, Young L, Surwit E . Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide). Invest New Drugs. 1984; 2(2):141-8. DOI: 10.1007/BF00232343. View

11.

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

12.

Twentyman P, LUSCOMBE M . A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 1987; 56(3):279-85. PMC: 2002206. DOI: 10.1038/bjc.1987.190. View

13.

BERENBAUM M . What is synergy?. Pharmacol Rev. 1989; 41(2):93-141. View

14.

Greco W, Park H, Rustum Y . Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1990; 50(17):5318-27. View

15.

Cheng M, Chatterjee S, Berger N . Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res. 1994; 6(6):269-79. View

16.

Masumoto N, Nakano S, Esaki T, Tatsumoto T, Fujishima H, Baba E . Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. Anticancer Res. 1995; 15(2):405-9. View

17.

Greco W, Bravo G, Parsons J . The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995; 47(2):331-85. View

18.

Blaney S, Phillips P, Packer R, Heideman R, Berg S, Adamson P . Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996; 78(3):527-31. DOI: 10.1002/(SICI)1097-0142(19960801)78:3<527::AID-CNCR21>3.0.CO;2-#. View

19.

Rowinsky E, Kaufmann S, Baker S, Grochow L, Chen T, Peereboom D . Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol. 1996; 14(12):3074-84. DOI: 10.1200/JCO.1996.14.12.3074. View

20.

Ma J, Maliepaard M, Nooter K, Boersma A, Verweij J, Stoter G . Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol. 1998; 41(4):307-16. DOI: 10.1007/s002800050744. View